3-SUBSTITUTED DERIVATIVES OF PYRIDO [3',4',4,5] THIENE [2,3-D] PYRIMIDINE, METHOD OF OBTAINING THEM AND THEIR APPLICATION

    公开(公告)号:PL337454A1

    公开(公告)日:2000-08-14

    申请号:PL33745498

    申请日:1998-05-29

    Applicant: BASF AG

    Abstract: PCT No. PCT/EP98/03231 Sec. 371 Date Dec. 8, 1999 Sec. 102(e) Date Dec. 8, 1999 PCT Filed May 29, 1998 PCT Pub. No. WO98/56793 PCT Pub. Date Dec. 17, 19983-Substituted 3,4,5,6,7,8-hexahydropyrido [3',4':4,5]-thieno[2,3-d]pyrimidine derivatives of the formula I where R1 is a hydrogen atom, a C1-C4-alkyl group, an acetyl group, a phenylalkyl C1-C4 radical, the aromatic system being unsubstituted or substituted by halogen, C1-C4-alkyl, trifluoromethyl, hydroxyl, C1-C4-alkoxy, amino, cyano or nitro groups, or is a phenylalkanone radical, it being possible for the phenyl group to be substituted by halogen, R2 is a phenyl, pyridyl, pyrimidinyl or pyrazinyl group which is unsubstituted or mono- or disubstituted by halogen atoms, C1-C4-alkyl, trifluoromethyl, trifluoromethoxy, hydroxyl, C1-C4-alkoxy, amino, monomethylamino, dimethylamino, cyano or nitro groups and which may be fused to a benzene nucleus which can be unsubstituted or mono- or disubstituted by halogen atoms, C1-C4-alkyl, hydroxyl, trifluoromethyl, C1-C4-alkoxy, amino, cyano or nitro groups and may contain 1 nitrogen atom, or to a 5- or 6-membered ring which may contain 1-2 oxygen atoms, A is NH or an oxygen atom, Y is CH2, CH2-CH2, CH2-CH2-CH2 or CH2-CH, Z is a nitrogen atom, carbon atom or CH, it also being possible for the linkage between Y and Z to be a double bond, and n is 2, 3 or 4, and the physiologically tolerated salts thereof.

    3-SUBSTITUTED PYRIDO [3',4':4,5] THIENO [2,3-D] PYRIMIDINE DERIVATIVES, AND PRODUCTION AND USE OF THE SAME

    公开(公告)号:SK174399A3

    公开(公告)日:2000-05-16

    申请号:SK174399

    申请日:1998-05-29

    Applicant: BASF AG

    Abstract: PCT No. PCT/EP98/03231 Sec. 371 Date Dec. 8, 1999 Sec. 102(e) Date Dec. 8, 1999 PCT Filed May 29, 1998 PCT Pub. No. WO98/56793 PCT Pub. Date Dec. 17, 19983-Substituted 3,4,5,6,7,8-hexahydropyrido [3',4':4,5]-thieno[2,3-d]pyrimidine derivatives of the formula I where R1 is a hydrogen atom, a C1-C4-alkyl group, an acetyl group, a phenylalkyl C1-C4 radical, the aromatic system being unsubstituted or substituted by halogen, C1-C4-alkyl, trifluoromethyl, hydroxyl, C1-C4-alkoxy, amino, cyano or nitro groups, or is a phenylalkanone radical, it being possible for the phenyl group to be substituted by halogen, R2 is a phenyl, pyridyl, pyrimidinyl or pyrazinyl group which is unsubstituted or mono- or disubstituted by halogen atoms, C1-C4-alkyl, trifluoromethyl, trifluoromethoxy, hydroxyl, C1-C4-alkoxy, amino, monomethylamino, dimethylamino, cyano or nitro groups and which may be fused to a benzene nucleus which can be unsubstituted or mono- or disubstituted by halogen atoms, C1-C4-alkyl, hydroxyl, trifluoromethyl, C1-C4-alkoxy, amino, cyano or nitro groups and may contain 1 nitrogen atom, or to a 5- or 6-membered ring which may contain 1-2 oxygen atoms, A is NH or an oxygen atom, Y is CH2, CH2-CH2, CH2-CH2-CH2 or CH2-CH, Z is a nitrogen atom, carbon atom or CH, it also being possible for the linkage between Y and Z to be a double bond, and n is 2, 3 or 4, and the physiologically tolerated salts thereof.

    Use of pyrimidine derivatives for the prophylaxis and therapy of cerebral ischemia

    公开(公告)号:NZ512767A

    公开(公告)日:2003-05-30

    申请号:NZ51276799

    申请日:1999-12-24

    Applicant: BASF AG

    Abstract: The use of pyrimidine derivatives of the formula (I) where: A is NH or oxygen; B is hydrogen or methyl; D is methyl; E is ¥ C ¥ Nr3R4 or Q% O D and E are together ûCH2-CH2-NR1-CH2-, -CH2-NR1-CH2- or -CH2-NR1-CH2-CH2-; X is nitrogen; Y is CH2, CH2-CH2, CH2-CH2-CH2 or CH2-CH; Z is nitrogen, carbon or CH, with it also being possible for the bond between Y and Z to be a double bond, N is the number 2, 3 or 4; R1 is hydrogen, a C1-C4-alkyl group, and acetyl or benzoyl group, a phenylalkyl C1-C4-alkyl group, an acetyl or benzoyl group, a phenylalkyl C1-C4 radical, with the aromatic moiety optionally being substituted by halogen, or C1-C4-alkyl, trifluoromethyl, hydroxy, C1-C4-alkoxy, amino, cyano or nitro groups, a napthylalkyl C1-C3 radical, a phenylalkanone C2-C3 radical or a phenylcarbamoylalkyl C2 radical, with it being possible for the phenyl group to be substituted by halogen; R2 is a phenyl, pyridyl, pyrimidinyl or pyrazinyl group which is optional monosubstituted, disubstituted or trisubstituted by halogen atoms, C1-C4-alkyl or be substituted by halogen, a C1-C4-alkyl group, a methoxy group and by a nitro or amino group; R2 is a phenyl, pyridyl, pyrimidinyl or pyrazinyl group which is optionally monosubstituted, disubstituted or trisubstituted by halogen atoms, C1-C4-alkyl or trifluoromethyl, trifluoromethoxy, hydroxyl, C1-C4-alkoxy, amino, monomethylamino, dimethylamino, cyano or nitro groups and which can optionally be fused to a benzene nucleus which can optionally be monosubstituted or disubstituted by halogen atoms, C1-C4-alkyl or hydroxyl, trifluoromethyl, C1-C4-alkoxy, amino, cyano or nitro groups and which can optionally contain 1 nitrogen atom, or to a 5- or 6-membered ring which can contain 1-2 oxygen atoms, or can be substituted by a phenyl-C1-C2-alkyl- or ûalkoxy group, with it being possible for the phenyl radical to be substituted by halogen, or a methyl, trifluoromethyl or methoxy group; R3 and R4 are, independently of each other, hydrogen or a C1-C4-alkyl group, and of their physiologically tolerated salts for producing medicaments for the prophylaxis and treatment of cerebral ischemia and strokes.

Patent Agency Ranking